How to buy Praxis Precision Medicines stock - 03 March

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Praxis Precision Medicines stock

Own Praxis Precision Medicines stock in just a few minutes.

Updated . What changed?

Fact checked

Praxis Precision Medicines, Inc is a biotechnology business based in the US. Praxis Precision Medicines shares (PRAX) are listed on the NASDAQ and all prices are listed in US Dollars. Praxis Precision Medicines employs 50 staff and has a market cap (total outstanding shares value) of USD$1.4 billion.

How to buy shares in Praxis Precision Medicines

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Praxis Precision Medicines. Find the stock by name or ticker symbol: PRAX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Praxis Precision Medicines reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Praxis Precision Medicines, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Praxis Precision Medicines. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Praxis Precision Medicines share price

Use our graph to track the performance of PRAX stocks over time.

Praxis Precision Medicines shares at a glance

Information last updated 2021-03-03.
52-week rangeUSD$19 - USD$60.9505
50-day moving average USD$52.1221
200-day moving average USD$44.9354
Wall St. target priceUSD$65.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Praxis Precision Medicines shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Tastyworks
$0
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Praxis Precision Medicines stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Praxis Precision Medicines financials

Gross profit TTM USD$0
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin 0%
Book value N/A
Market capitalisation USD$1.4 billion

TTM: trailing 12 months

Shorting Praxis Precision Medicines shares

There are currently 892,701 Praxis Precision Medicines shares held short by investors – that's known as Praxis Precision Medicines's "short interest". This figure is 35.5% down from 1.4 million last month.

There are a few different ways that this level of interest in shorting Praxis Precision Medicines shares can be evaluated.

Praxis Precision Medicines's "short interest ratio" (SIR)

Praxis Precision Medicines's "short interest ratio" (SIR) is the quantity of Praxis Precision Medicines shares currently shorted divided by the average quantity of Praxis Precision Medicines shares traded daily (recently around 102022.97142857). Praxis Precision Medicines's SIR currently stands at 8.75. In other words for every 100,000 Praxis Precision Medicines shares traded daily on the market, roughly 8750 shares are currently held short.

To gain some more context, you can compare Praxis Precision Medicines's short interest ratio against those of similar companies.

However Praxis Precision Medicines's short interest can also be evaluated against the total number of Praxis Precision Medicines shares, or, against the total number of tradable Praxis Precision Medicines shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Praxis Precision Medicines's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Praxis Precision Medicines shares in existence, roughly 20 shares are currently held short) or 0.0336% of the tradable shares (for every 100,000 tradable Praxis Precision Medicines shares, roughly 34 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Praxis Precision Medicines.

Find out more about how you can short Praxis Precision Medicines stock.

Praxis Precision Medicines share dividends

We're not expecting Praxis Precision Medicines to pay a dividend over the next 12 months.

You may also wish to consider:

Praxis Precision Medicines overview

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement Purdue Neuroscience Company; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was incorporated in 2015 and is based in Cambridge, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site